Atlas Trials

Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Clinical trial NCT03093831 · TERMINATED

Trial details

NCT number
NCT03093831
Sponsor
National Cancer Centre, Singapore
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Lymphoma, B-Cell, Marginal Zone
Start date
2016-07-08
Primary completion
2020-07-17
Enrollment
5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.